Biovica signs European agreement
Biovica International has landed an agreement with French Eurobio Scientific, giving the company access to 60 percent of the European market for its diagnostic test DiviTum TKa.
Uppsala-based Biovica has developed DiviTum TKa, a diagnostic biomarker test used to evaluate and predict treatment response in various forms of cancer. According to a number of independent studies, DiviTum TKa can provide information about cell division several months before it can be measured as changed tumor volume using imaging.
That way, the treating physician gets an important complement in the diagnostic toolbox, and access to an early indication of whether the treatment is working or not.
The agreement with Eurobio Scientific covers France, the Benelux countries, Germany, the United Kingdom and Austria – markets that together account for a significant part of Europe’s potential for the product. The French diagnostics specialist manufactures and commercializes tests in transplantation, immunology and infectious diseases, and its products are primarily sold to research laboratories.
Confident in strong sales
– Eurobio Scientific has proven itself as a strong European-based distributor with impressive growth in several areas of in-vitro diagnostics, comments Biovica’s CEO Anders Rylander. With the help of the sales force, they took over from Myriad Genetics in Europe, we are certain they will achieve strong European sales. We are delighted to sign a comprehensive agreement with such a successful and dynamic company making DiviTum TKa available for patients on the largest markets in Europe,
The newly signed agreement is an important milestone for the company in the process of establishing the product around the world. At the end of last year, their CLIA lab in San Diego received permission from the New York State Department of Health, opening the entire US market for the test. Soon after, they signed an agreement with an American health insurance giant to include DiviTum TKa in their coverage. And as icing on the cake, Biovica started 2025 with an order for TKa testing services from a large pharmaceutical company worth SEK 2.3 million.
Backed by the stream of good news, the company has set eyes on achieving positive cash flow for the business. The next quarter report, released on March 13, will tell us more about how far down that road they have come.
